Toronto, Ontario – June 3, 2022 (Newsfile Corp.) (Investorideas.com Newswire) VIVO Hashish Inc. (TSX: VIVO) (OTCQX: VVCIF) (“VIVO” or the “Firm”), a number one supplier of medical hashish merchandise and affected person providers, and holder of licenses below the Hashish Act via its wholly-owned subsidiaries, Canna Farms Restricted (“Canna Farms”), ABcann Medicinals Inc., right now introduced outcomes from its first examine investigating how medical hashish impacts anxiousness and melancholy outcomes. The publication, entitled “Medical hashish use in Canada and its impression on anxiousness and melancholy: A retrospective examine” was printed within the peer-reviewed journal Psychiatry Analysis and was accomplished by VIVO’s Harvest Drugs Inc (“HMED”) subsidiary. To the Firm’s information, it’s the largest examine to this point of its form, analyzing the impression of medical hashish utilizing longitudinal knowledge and accomplished validated questionnaires for anxiousness (GAD-7) and melancholy (PHQ-9) in 7,362 Canadian sufferers. Analyses had been carried out for 3 totally different timepoints: 3-6 months, 12-18 months, and 24 months or better.
The examine was led by HMED’s group of prescribing clinicians and doctor assist workers. Sufferers utilizing medical hashish for anxiousness and/or melancholy noticed statistically vital improved outcomes between baseline and follow-up scores. This study supplies some proof to assist the effectiveness of medical hashish as a therapy for anxiousness and melancholy.
“Since 2017, Harvest Drugs has been an industry-leading, excessive quantity hashish clinic community, and our group has labored laborious to share these scientific insights in an effort to contribute to the medical hashish literature and to cut back stigma amongst well being care professionals,” stated Carole Chan, RPh, President of Harvest Drugs. “We’re dedicated to additional analysis and advancing affected person outcomes with an evidence-informed strategy to affected person care.”
About VIVO Hashish
VIVO Hashish® is acknowledged for trusted, premium hashish services. By way of its Canna Farms and ABcann enterprise items, VIVO holds manufacturing and gross sales licences from Well being Canada and operates world-class indoor cultivation services. VIVO has a set of premium manufacturers, every concentrating on totally different buyer segments, together with Canna Farms™, Beacon Medical®, Hearth™, and Lumina™. Harvest Drugs™, VIVO’s patient-centric, scalable community of medical hashish clinics, has serviced over 200,000 affected person visits. VIVO is pursuing a number of partnership and product improvement alternatives and is focusing its worldwide efforts on Germany and Australia. For extra info go to: www.vivocannabis.com
For additional info:
VIVO Investor Relations
Michael Bumby, Chief Monetary Officer
Disclaimer for Ahead-Trying Data
Sure statements on this information launch are forward-looking statements, that are statements that aren’t purely historic, together with statements relating to the beliefs, plans, expectations or intentions of VIVO and its administration relating to the long run. Such statements are topic to dangers and uncertainties that will trigger precise outcomes, efficiency or developments to vary materially from these contained within the ahead‐wanting statements. No assurance might be provided that any of the occasions anticipated by the ahead‐wanting statements will happen or, in the event that they do happen, what advantages the Firm will receive from them. Readers are urged to think about these elements fastidiously together with the extra intensive threat elements included within the Firm’s most up-to-date administration’s dialogue and evaluation accessible on SEDAR, in evaluating the ahead‐wanting statements contained on this information launch and are cautioned to not place undue reliance on such ahead‐wanting statements, that are certified of their entirety by these cautionary statements. The ahead‐wanting statements on this information launch are made as of the date hereof and the Firm disclaims any intent or obligation to replace publicly any such ahead‐wanting statements, whether or not on account of new info, future occasions or outcomes or in any other case, besides as required by relevant securities legal guidelines.
Disclaimer/Disclosure: Investorideas.com is a digital writer of third celebration sourced information, articles and fairness analysis in addition to creates authentic content material, together with video, interviews and articles. Unique content material created by investorideas is protected by copyright legal guidelines apart from syndication rights. Our web site doesn’t make suggestions for purchases or sale of shares, providers or merchandise. Nothing on our websites ought to be construed as a proposal or solicitation to purchase or promote merchandise or securities. All investing entails threat and doable losses. This web site is at present compensated for information publication and distribution, social media and advertising, content material creation and extra. Disclosure is posted for every compensated information launch, content material printed /created if required however in any other case the information was not compensated for and was printed for the only real curiosity of our readers and followers. Contact administration and IR of every firm instantly relating to particular questions.
Extra disclaimer data: https://www.investorideas.com/About/Disclaimer.asp Study extra about publishing your information launch and our different information providers on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
World buyers should adhere to laws of every nation. Please learn Investorideas.com privateness coverage: https://www.investorideas.com/About/Private_Policy.asp